Novel screening method

Abstract

By using a G protein-coupled receptor protein comprising an amino acid sequence, which is the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, and an ionizable metal element or a salt thereof, an agonist for or an antagonist to the above receptor protein or a salt thereof can be efficiently screened.

Description

TECHNICAL FIELD [0001] The present invention relates to use of a G protein-coupled receptor protein (GPR39). BACKGROUND ART [0002] Physiological active substances such as various hormones, neurotransmitters, etc. regulate the biological function via specific receptor proteins present on cell membranes. Many of these receptor proteins are coupled with guanine nucleotide-binding protein (hereinafter sometimes simply referred to as G protein) and mediate the intracellular signal transduction via activation of G protein. These receptor proteins possess the common structure containing seven transmembrane domains and are thus collectively referred to as G protein-coupled receptor proteins (GPCR) or seven-transmembrane receptor proteins (7TMR). [0003] G protein-coupled receptor proteins are present on the cell surface of each functional cell and organ in the body, and play a vitally important physiological role as the target of the molecules that regulate the functions of the cells and org...

AI Technical Summary

Benefits of technology

[0071] [55] A method for confirming that a drug for preventing / treating growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression or menoxenia, renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy or Wilson's disease binds to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using said receptor protein or a salt thereof.

[0072] [56] A method for confirming that a drug for preventing / treating hypotonic bladder induced by sensory decrease of the bladder, hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs, overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria, prostatic hyperplasia-induced pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms or various disorders caused by urinary calculus, an agent for regulating the secretion of cytokines (e.g., IL-8) or a drug for preventing / treating inflammatory diseases (e.g., diabetic complications such as neuropathy, macroangiopathy, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia) or allergic diseases (e.g., asthma, atopic dermatitis or chronic obstructive pulmonary disease (COPD)) binds to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using said receptor protein, or a salt thereof.

[0073] [57] A method for confirming that a drug for preventing / treating growth retardation, wounds, burn, cold constitution, declining of learning ability, hypogonadism, dysgeusia, anosmia, hyperplasia, arteriosclerosis, myocardial infarction, apoplexy, cirrhosis, cholesterol accumulation, lowered resistance to infection, gout, cancer, hard labor, diabetes mellitus, brown spots, anemia, alopecia, respiratory disturbances, indigestion, cardiac disturbances, gray hair, puffiness, wrinkles, saggings, hypothyroidism, depression or menoxenia is an agonist for a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using said receptor protein or a salt thereof.

[0074] [58] A method for confirming that a drug for preventing / treating hypotonic bladder induced by sensory decrease of the bladder or hypotonic bladder induced by postsurgical bladder anesthesia of the pelvic organs or a drug for promoting the secretion of cytokines (e.g., IL-8) is an agonist for a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using said receptor protein or a salt thereof.

[0075] [59] A method for confirming that a drug for preventing / treating renal dysfunction, pulmonary dysfunction, allergic dermatitis, sensory neuropathy or Wilson's disease is an antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using said receptor protein or a salt thereof.

[0076] [60] A method for confirming that a drug for preventing / treating overactive bladder-induced pollakiuria, nocturia, cystitis-induced pollakiuria, prostatic hyperplasia-induced pollakiuria, urinary incontinence, urinary urgency, pelvic visceral pain, coital pain, bladder irritation symptoms or various disorders caused by urinary calculus, a drug for suppressing the secretion of cytokines (e.g., IL-8) or a drug for preventing / treating inflammatory diseases (e.g., diabetic complications such as neuropathy, macroangiopathy, etc.; inflammatory bowel diseases such as ulcerative colitis, etc.; cystitis; irritable bowel syndrome; neuralgia) or allergic diseases (e.g., asthma, atopic dermatitis or chronic obstructive pulmonary disease (COPD)) is an antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using said receptor protein or a salt thereof.

Problems solved by technology

However, since many ESTs or genome sequences contain sequence information only, it is difficult to predict their functions.

However, functions of these G protein-coupled receptor proteins and their physiological ligands remain unresolved.

Furthermore, the decreased or increased functions of G protein-coupled receptor proteins due to genetic aberration of the G protein-coupled receptor proteins in the body often cause some disorders.

Images